Guidance and quality standards Awaiting development

Skip to filtersSkip to results

Skip to results

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 101 to 150 of 309

TitleType
Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6338]Technology appraisal guidance
Estetrol for treating vasomotor symptoms associated with the menopause in people aged 40 to 65 ID4037Technology appraisal guidance
Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]Technology appraisal guidance
Evinacumab for treating homozygous familial hypercholesterolemia in children aged 5 to 11 TS ID 11806Technology appraisal guidance
Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920Technology appraisal guidance
Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]Technology appraisal guidance
Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment TS ID 11963Technology appraisal guidance
Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133]Technology appraisal guidance
Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]Technology appraisal guidance
Galcanezumab for migraine TS ID 10663Technology appraisal guidance
Gantenerumab for treating early Alzheimer's disease TS ID 10668Technology appraisal guidance
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over ID6394Technology appraisal guidance
Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID 5072]Technology appraisal guidance
Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A TS ID 9772Technology appraisal guidance
Gosuranemab for treating progressive supranuclear palsy [ID1607]Technology appraisal guidance
Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]Technology appraisal guidance
Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747]Technology appraisal guidance
Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]Technology appraisal guidance
Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 therapies TS ID 10330Technology appraisal guidance
Inavolisib with palbociclib and fulvestrant for treating HR+/HER2-, PIK3CA mutated locally advanced or metastatic breast cancer TS ID 11990Technology appraisal guidance
Inebilizumab for treating AQP4-IgG seropositive neuromyelitis optica spectrum disorders ID6430Technology appraisal guidance
Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]Technology appraisal guidance
Insulin icodec for treating type 1 and type 2 diabetes TS ID 11770Technology appraisal guidance
Intravascular lithotripsy for calcified coronary arteries during percutaneous coronary interventionInterventional procedures guidance
Invimestrocel for treating acute ischaemic stroke within 18 to 36 hours of onset TS ID 10190Technology appraisal guidance
Iptacopan for treating complement 3 glomerulopathy TS ID 10435Technology appraisal guidance
Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable TS ID 11949Technology appraisal guidance
Isatuximab in combination for newly diagnosed multiple myeloma [ID3981]Technology appraisal guidance
Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]Technology appraisal guidance
Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]Technology appraisal guidance
Laparoscopic insertion of a non-active implant for gastro-oesophageal reflux diseaseInterventional procedures guidance
Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor TS ID 11822Technology appraisal guidance
Leadless cardiac pacemaker implantation for bradyarrhythmiasInterventional procedures guidance
Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]Technology appraisal guidance
Leriglitazone for treating X-linked andrenoleukodystrophy TS ID 9996Technology appraisal guidance
Letermovir for preventing cytomegalovirus infection in people under 18 years after allogeneic haematopoietic stem cell transplant TS ID 11868Technology appraisal guidance
Letetresgene autoleucel for treating NY-ESO-1 advanced unresectable synovial sarcoma in people aged 10 and over or NY-ESO-1 advanced unresectable myxoid round cell liposarcoma in adults TS ID 10652Technology appraisal guidance
Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer TS ID 10203Technology appraisal guidance
Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]Technology appraisal guidance
Linerixibat for treating pruritus in people with primary biliary cholangitis TS ID 10136Technology appraisal guidance
Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]Technology appraisal guidance
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]Technology appraisal guidance
Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer TS ID 11970Technology appraisal guidance
Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]Technology appraisal guidance
Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]Technology appraisal guidance
Magrolimab with azacitidine for untreated myelodysplastic syndromes [ID3978]Technology appraisal guidance
Masitinib with riluzole for treating amyotrophic lateral sclerosis TS ID 10728Technology appraisal guidance
Mavorixafor for treating WHIM syndrome ID3946Technology appraisal guidance
Mepolizumab for treating chronic obstructive pulmonary disease [ID1237]Technology appraisal guidance
MIM8 for preventing bleeding episodes in haemophilia A in people 1 year and over ID6400Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All